Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We generated a human induced pluripotent stem cell (iPSC) line from the peripheral blood mononuclear cells isolated from a 59-year-old male patient with Alzheimer's disease (AD). The iPSC line was meticulously characterized to confirm its pluripotency, absence of transgenes, and normal karyotype. The unexpected discovery of the M232R variant in PRNP makes this cell line a valuable resource for investigating AD pathogenesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.scr.2024.103361 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced Biomaterial Delivery of Hypoxia-Conditioned Extracellular Vesicles (EVs) as a Therapeutic Platform for Traumatic Brain Injury.
Adv Sci (Weinh)
September 2025
Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Traumatic Brain Injury (TBI) is a common and debilitating injury, causing long-lasting neurological deficits. Current therapeies for recovery remain inadequate, undersing the urgent need for innovative interventions. In this study, a novel therapeutic approach is introduced that delivers extracellular vesicles (EVs) derived from human-induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) with a gelatin-based injectable bioorthogonal hydrogel (BIOGEL).
View Article and Find Full Text PDFA human striatal-midbrain assembloid model of alpha-synuclein propagation.
Brain
September 2025
Okinawa Institute of Science and Technology Graduate University, Okinawa, 904-0495, Japan.
Animal models of the pathology of Parkinson's disease (PD) have provided most of the treatments to date, but the disease is restricted to human patients. In vitro models using human pluripotent stem cells (hPSCs)-derived neural organoids have provided improved access to study PD etiology. This study established a method to generate human striatal-midbrain assembloids (hSMAs) from hPSCs for modeling alpha-synuclein (α-syn) propagation and recapitulating basal ganglia circuits, including nigrostriatal and striatonigral pathways.
View Article and Find Full Text PDFIntegral approach to organelle profiling in human iPSC-derived cardiomyocytes enhances cardiac safety classification of known cardiotoxic compounds.
Front Toxicol
August 2025
Ncardia Services B.V., Leiden, Netherlands.
Introduction: Efficient preclinical prediction of cardiovascular side effects poses a pivotal challenge for the pharmaceutical industry. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are becoming increasingly important in this field due to inaccessibility of human native cardiac tissue. Current preclinical hiPSC-CMs models focus on functional changes such as electrophysiological abnormalities, however other parameters, such as structural toxicity, remain less understood.
View Article and Find Full Text PDFNon-invasive maturity assessment of iPSC-CMs based on optical maturity characteristics using interpretable AI.
Comput Struct Biotechnol J
August 2025
Institute of Biomedical Engineering, TU Dresden, Fetscherstr. 29, Dresden 01307, Germany.
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) are an important resource for identifying novel therapeutic targets and cardioprotective drugs. However, a key limitation of iPSC-CMs is their immature, fetal-like phenotype. Cultivation of iPSC-CMs in lipid-supplemented maturation media (MM) enhances the structural, metabolic and electrophysiological properties of iPSC-CMs.
View Article and Find Full Text PDFGenetics of Congenital Heart Disease: A Narrative Review of Challenges and Strategies in Identifying Novel Genes.
Cureus
September 2025
Department of Paediatric Histopathology, Alder Hey Children's Hospital, Liverpool, GBR.
Congenital heart disease (CHD) is the most common congenital anomaly. While surgical and interventional advancements have improved survival, the management of associated complications and comorbidities remains complex and would benefit from a personalised approach that more accurately predicts individualised risks and prognoses. Recently, next-generation sequencing has uncovered diverse genetic factors, including epigenetic modifications, somatic mosaicism and regulatory non-coding variants.
View Article and Find Full Text PDF